OpenAI is rolling out significant upgrades to its GPT-Rosalind AI model, specifically targeting the complex demands of life sciences research and drug discovery. The updated model, built on the foundation of OpenAI GPT-5.5, now boasts enhanced agentic coding, tool-use capabilities, and deeper intelligence in critical areas like medicinal chemistry and genomics.
This advancement aims to bridge the gap between AI-driven reasoning and the practical execution of scientific workflows. GPT-Rosalind's improvements are designed to synthesize data across various scales, from molecules to living systems, a crucial aspect of progress in the field.